Radiopharm Theranostics Limited (RADX) prices 384,493,800 shares at AUD 0.015
Rhea-AI Filing Summary
Radiopharm Theranostics Limited issued 384,493,800 new RAD ordinary fully paid shares for cash at AUD 0.01500000 per share, to be quoted on ASX from 28 July 2026 as part of a placement previously outlined in an Appendix 3B.
The company states that further securities remain to be issued under that transaction, including 448,839,531 additional ordinary shares, 448,839,531 options expiring 31-Jul-2029 with an exercise price of 0.018, and ADR warrants of 64,082 and 1,281,646 expiring 31-Jul-2029 with exercise prices of USD 3.95 and USD 3.79.
Following quotation of the new shares, RAD ordinary fully paid shares on issue will total 3,928,709,960, alongside multiple quoted option series such as RADAN options, which number 387,179,525 and have various expiries and exercise prices.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Application for quotation of securities regulatory
Appendix 3B regulatory
Section 708A(5)(e) of the Corporations Act 2001 regulatory
ADR WARRANTS financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Radiopharm Theranostics Limited (RADX) announce on 28 July 2026?
What additional securities are yet to be issued under Radiopharm Theranostics' (RADX) placement?
What notice did RADX give under Section 708A(5)(e) of the Corporations Act 2001?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on July 28, 2026 titled:
| - |
“Application for quotation of securities - RAD” |
| - | “Notice Under Section 708A” |
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.
1
EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Application for quotation of securities - RAD | |
| 99.2 | Notice Under Section 708A |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
| Date: July 28, 2026 | By: | /s/ Amritha Sushil |
| Amritha Sushil | ||
| Company Secretary | ||
3
Exhibit 99.1
 |
Appendix 2A - Application for quotation of securities |
Announcement Summary
Entity name
RADIOPHARM THERANOSTICS LIMITED
Announcement Type
New announcement
Date of this announcement
Tuesday July 28, 2026
The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
Total number of +securities to be quoted
| ASX +security code | Security description | Number of +securities to be quoted | Issue date |
| RAD | ORDINARY FULLY PAID | 384,493,800 | 28/07/2026 |
Refer to next page for full details of the announcement
| Appendix 2A - Application for quotation of securities | 1/6 |
| |
Appendix 2A - Application for quotation of securities |
Part 1 - Entity and announcement details
| 1.1 | Name of entity |
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
| 1.2 | Registered Number Type | Registration Number | |
| ACN | 647877889 | ||
| 1.3 | ASX issuer code |
RAD
| 1.4 | The announcement is |
New announcement
| 1.5 | Date of this announcement |
28/7/2026
| Appendix 2A - Application for quotation of securities | 2/6 |
| |
Appendix 2A - Application for quotation of securities |
Part 2 - Type of Issue
| 2.1 | The +securities to be quoted are: |
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
Previous Appendix 3B details:
| Announcement and Time | Announcement Title | Selected Appendix 3B to submit quotation request | |||
| 24-.01-2026 17:21 | New - Proposed issue of securities RAD | A placement or other type of issue |
2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?
Yes
2.3a.3 Please provide details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B
| 448,839,531 | RAD ORDINARY FULLY PAID | |
| 448,839,531 | New class OPTION EXPIRING 31-JUL-2029 EX 0.018 | |
| 64,082 | New class ADR WARRANTS EXPIRING 31-JUL-2029 EX USD 3.95 | |
| 1,281,646 | New class ADR WARRANTS EXPIRING 31-JUL-2029 EX USD 3.79 |
| Appendix 2A - Application for quotation of securities | 3/6 |
| |
Appendix 2A - Application for quotation of securities |
Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B
Placement Details
ASX +security code and description
RAD : ORDINARY FULLY PAID
Issue date
28/7/2026
Distribution Schedule
Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category.
| Number of +securities held | Number of holders | Total percentage of +securities held For example, to enter a value of 50% please input as 50.00 | ||
| 1 - 1,000 | % | |||
| 1,001 - 5,000 | % | |||
| 5,001 - 10,000 | % | |||
| 10,001 - 100,000 | % | |||
| 100,001 and over | % |
| Appendix 2A - Application for quotation of securities | 4/6 |
| |
Appendix 2A - Application for quotation of securities |
Issue details
Number of +securities to be quoted
384,493,800
Are the +securities being issued for a cash consideration?
Yes
| In what currency is the cash consideration being paid? | What is the issue price per +security? | ||
| AUD - Australian Dollar | AUD 0.01500000 |
Any other information the entity wishes to provide about the +securities to be quoted
| Per placement announcement dated 24 July 2026, 1,281,646 American Depositary Shares (ADS) issued representing 384,493,800 underlying RAD ordinary shares |
| Appendix 2A - Application for quotation of securities | 5/6 |
| |
Appendix 2A - Application for quotation of securities |
Part 4 - Issued capital following quotation
Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)
| ASX +security code and description | Total number of +securities on issue | |||
| RADO : OPTION EXPIRING 30-NOV-2026 | 79,352,040 | |||
| RAD : ORDINARY FULLY PAID | 3,928,709,960 | |||
| RADOA : OPTION EXPIRING 24-AUG-2026 | 818,890,534 | |||
| RADOB : OPTION EXPIRING 31-OCT-2027 | 1,179,266,658 | |||
| 4.2 | Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX) |
| ASX +security code and description | Total
number of +securities on issue | |||
| RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60 | 1,666,500 | |||
| RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 387,179,525 | |||
| RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17 | 12,425,675 | |||
| RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED | 8,666,678 | |||
| RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60 | 5,066,672 | |||
| RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60 | 740,000 | |||
| RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09 | 8,955,224 | |||
| Appendix 2A - Application for quotation of securities | 6/6 |
Exhibit 99.2
ASX ANNOUNCEMENT
28 July 2026
Notice Under Section 708A(5)(e) of the Corporations Act 2001
This notice is given by Radiopharm Theranostics Limited (ASX:RAD) (‘RAD’ or the ‘Company’) undersection 708A(5)(e) of the Corporations Act 2001 (Cth) (the ‘Corporations Act’)..
| Class of securities: | Ordinary Fully Paid Shares |
| ASX Code | RAD |
| Date of issue | 28 July 2026 |
| Number issued | 384,493,800 |
The Company gives notice under section 708(5)(e) of the Corporations Act that:
| 1 | the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; |
| 2 | at the date of this notice, the Company has complied with: |
| a. | the provisions of chapter 2M of the Corporations Act as they apply to the Company; and |
| b. | sections 674 and 674A Corporations Act; and |
| 3 | at the date of this notice, there is no information required to be disclosed by the Company which is ‘excluded information’ (as defined in sections 708A(7) and 708A(8) Corporations Act). |
Amritha Sushil
Joint Company Secretary
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889